Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,866 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06897644RecruitingPhase 3
Comparing two chemotherapy strategies for advanced pancreatic cancer
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
AvianoAges 18 years+ - NCT06673628RecruitingPhase 2
Pembrolizumab plus lenvatinib for skin angiosarcoma
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
KashiwaAges 18–85 - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT05649943Recruiting
New prostate cancer treatment plus local therapy for metastatic cases
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Milan, LombardyAges 18 years+ - NCT06514521Recruiting
Study of Pluvicto for prostate cancer in Korea
This study is for men with prostate cancer who are being treated with or are scheduled to receive the drug Pluvicto in South Korea. It aims to track real-world results and safety.
Seongnam-si, Gyeonggi-doAges 18–100 - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Orange, CaliforniaAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05278052RecruitingPhase 3
Maintenance therapy alone versus radiation plus maintenance for lung cancer
This trial compares standard maintenance treatment versus adding focused radiation to remaining limited (oligometastatic) spots in the body after initial chemotherapy. It aims to see whether treating those limited spots with radiation can improve outcomes without unacceptable side effects.
Mumbai, MaharashtraAges 18–99 - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06155084RecruitingPhase 1/Phase 2
HP518 for advanced prostate cancer that has spread
This trial tests an oral drug called HP518 for men with a specific genetic change in their prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The goal is to see if HP518 can control the cancer.
Hefei, AnhuiAges 18 years+ - NCT06107686RecruitingPhase 2
YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
Hefei, AnhuiAges 18–75 - NCT06100705RecruitingPhase 2
Immunotherapy plus testosterone for advanced prostate cancer
This study combines an immunotherapy drug called sipuleucel-T (which boosts your immune system to fight cancer) with a high-dose testosterone treatment called bipolar androgen therapy. The goal is to see if this combination can help men with advanced prostate cancer that is not responding to usual hormone therapy.
New Haven, ConnecticutAges 18 years+ - NCT06006013RecruitingPhase 2
Cabozantinib and pembrolizumab for adrenal cancer
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
Atlanta, GeorgiaAges 18 years+ - NCT05743621RecruitingPhase 1
First TVB-2640 and enzalutamide for metastatic prostate cancer
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
New York, New YorkAges 18 years+ - NCT05762536RecruitingPhase 2
Docetaxel or cabazitaxel with or without darolutamide
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
RotterdamAges 18 years+ - NCT05700461RecruitingPhase 1
Testing a new implant drug delivery device for kidney cancer
This early-phase study tests a new small implant (“IMD”) that can deliver a drug for people with kidney cancer going to surgery. If you qualify, you would get the implant placed through the skin and later have it removed during your operation, along with extra lab checks and genetic testing.
Boston, MassachusettsAges 18 years+ - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT06800768Recruiting
PET scan for finding thyroid cancer that has returned after surgery
This trial tests a special PET scan (68Ga-FAPI) to see if it can better find thyroid cancer that has come back or spread after surgery. It may help your doctor decide on the best next steps for your care.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07218913RecruitingPhase 1
Testing a drug to reduce ear damage from chemo in testicular cancer
This trial tests whether adding Pedmark (sodium thiosulfate) to cisplatin chemotherapy can protect hearing in men with stage II or III testicular germ cell tumors. It aims to reduce the risk of drug-related ear damage while still treating the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,866 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.